1-[3-(4-羟基-苯基)-5-(4-甲氧基-苯基)-4,5-二氢-吡唑-1-基]-乙酮 | 148404-10-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-[3-(4-羟基-苯基)-5-(4-甲氧基-苯基)-4,5-二氢-吡唑-1-基]-乙酮
• 英文名称: 1-(3-(4-Hydroxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone
• 英文别名: 1-(4,5-Dihydro-3-(4-hydroxyphenyl)-5-(4-methoxyphenyl)pyrazol-1-yl)ethanone；1-[3-(4-Hydroxy-phenyl)-5-(4-methoxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-ethanone；1-[5-(4-hydroxyphenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]ethanone
• CAS: 148404-10-8
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: DBHNGALCTKSHMU-UHFFFAOYSA-N

物化性质

• 熔点：
  217-218 °C
• 沸点：
  494.7±55.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

α淀粉酶-IN-1（化合物11）是一种α-淀粉酶抑制剂，其IC50值为0.5509 μM。此外，它还具有抗氧化活性，能够清除DPPH自由基，其IC50值为53.49 μM。这些性质使其适用于糖尿病和氧化应激相关疾病的科研工作。[1]

反应信息

• 作为反应物：
  描述：

  1-[3-(4-羟基-苯基)-5-(4-甲氧基-苯基)-4,5-二氢-吡唑-1-基]-乙酮 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 1-(3-(4-((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-4,5-dihydro-5-(4-methoxyphenyl)pyrazol-1-yl)ethanone
  参考文献：
  名称：

  通过点击化学合成1,2,3-三唑系留双功能杂化物及其细胞毒性研究

  摘要：

  考虑到目前使用的大多数抗癌药物的耐药性，已合成了吡唑基查耳酮和由三唑环束缚的对硝基苄基官能团的分子杂合物，并评估了其对三种人类癌细胞系（THP，COLO-205）的细胞毒性研究，A-549）。初步研究的结果显示出细胞毒性活性对电子因子的显着依赖性。萘基（JGPT-11）和三甲氧基苯基环（JGPT-6）作为环A的放置被证明对增强细胞毒性潜力极为有利。因此，我们在本文中报道了新型分子杂合体的合成和细胞毒性研究。对JGPT-11和6的生物学机理的详细研究正在进行中。

  DOI：

  10.1007/s00044-012-0312-7
• 作为产物：
  描述：

  (E)-3-(4-Methoxy-phenyl)-1-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-propenone 在 盐酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 26.0h， 生成 1-[3-(4-羟基-苯基)-5-(4-甲氧基-苯基)-4,5-二氢-吡唑-1-基]-乙酮
  参考文献：
  名称：

  一些吡唑衍生物的合成及其与P-糖蛋白的亲和力结合的初步研究。

  摘要：

  合成了一系列取代的吡唑啉，并通过直接结合至包含ATP结合位点和调节剂相互作用区的纯化蛋白结构域，评估了它们的抗癌活性以及抑制P-糖蛋白介导的多药耐药性的能力。已经发现化合物2a和e以更大的亲和力与P-糖蛋白结合。

  DOI：

  10.1016/j.bmcl.2005.05.067

文献信息

• Structure-activity relationship with pyrazoline-based aromatic sulfamates as carbonic anhydrase isoforms I, II, IX and XII inhibitors: Synthesis and biological evaluation
  作者：Davide Moi、Alessio Nocentini、Alessandro Deplano、Gianfranco Balboni、Claudiu T. Supuran、Valentina Onnis

  DOI：10.1016/j.ejmech.2019.111638

  日期：2019.11

  Four new series of aromatic sulfamates were synthesized and investigated for the inhibition of four human (h) isoforms of zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), hCA I, II, IX, and XII. The reported derivatives, obtained by a sulfamoylation reaction of the corresponding phenolic precursors, bear 3,5-diarylpyrazoline moieties as spacers between the benzenesulfamate fragment which binds the

  合成了四个新系列的芳族氨基磺酸盐，并研究了它们对锌酶碳酸酐酶（CA，EC 4.2.1.1），hCA I，II，IX和XII的四种人（h）同工型的抑制作用。通过相应的酚类前体的氨磺酰化反应获得的已报道的衍生物带有3,5-二芳基吡唑啉部分，作为结合来自活性位点的锌离子的苯氨基磺酸盐片段和抑制剂尾巴之间的间隔基。吡唑啉是具有生物学优势的支架，具有多种生物活性，例如抗增殖作用。测试了这些衍生物对胞质，hCA I和II（脱靶同种型）和跨膜，与肿瘤相关的hCA IX和XII酶（抗癌靶标）的抑制作用。通常，hCA I不能被有效抑制，而许多低纳摩尔抑制剂被证明可抵抗hCA II（KIs在0.42-90.1 nM范围内），IX（KIs在0.72-63.6 nM范围内）和XII（KIs在0.88-85.2 nM范围内）。对于CA II，吡唑啉环上的最佳取代片段包括3-芳基上的4-氨基磺酸基和5-芳基上的卤素或
• Synthesis and in vitro selective anti-Helicobacter pylori activity of pyrazoline derivatives
  作者：F. Chimenti、B. Bizzarri、F. Manna、A. Bolasco、D. Secci、P. Chimenti、A. Granese、D. Rivanera、D. Lilli、M.M. Scaltrito、M.I. Brenciaglia

  DOI：10.1016/j.bmcl.2004.11.042

  日期：2005.2

  In order to develop new anti-Helicobacter pylori agents, a series of N1-substituted 3,5-diphenyl pyrazolines P1-P13 was prepared and evaluated for their antibacterial activity. All synthesized compounds showed little or no activity against different species of Gram-positive and Gram-negative bacteria of clinical relevance and against various strains of pathogenic fungi. The same derivatives exhibited

  为了开发新的抗幽门螺杆菌药物，制备了一系列N1取代的3,5-二苯基吡唑啉P1-P13，并对其抗菌活性进行了评估。所有合成的化合物对具有临床相关性的不同种类的革兰氏阳性细菌和革兰氏阴性细菌以及各种病原真菌菌株都几乎没有或没有活性。相同的衍生物对一系列幽门螺杆菌菌株（包括对参考化合物甲硝唑有抗性的菌株）表现出显着的活性。在所制备的化合物中，在5-苯环中具有N1-乙酰基和4-甲氧基取代基的化合物在1-4 microg / mL MIC范围内显示出对幽门螺杆菌甲硝唑耐药菌株的最佳活性。
• Synthesis and cytotoxicity studies of 3,5-diaryl N-acetyl pyrazoline—isatin hybrids
  作者：Manmohan Sharma、Sahil Sharma、Abhishek Buddhiraja、A. K. Saxena、Kunal Nepali、P. M. S. Bedi

  DOI：10.1007/s00044-014-1001-5

  日期：2014.10

  Numerous reports highlighting the cytotoxic effects of 3,5-diaryl N-acetyl-pyrazolines and isatin tempted us to synthesise conjugates of the functionalities via alkyl armed triazole tetheration. The hybrids were synthesized by click chemistry approach and were evaluated against a panel of cell lines i.e. viz HeLa (cervix cancer), CAKI-I (Renal cancer), PC-3 (Prostate cancer) and Miapaca-2 (pancreatic cancer). The hybrids were classified into right-handed and left-handed conjugates on the basis of the placement of the isatin ring. The length of the alkyl armed triazole linker was varied from 2 to 6. Structure activity relationship has also been presented. A preliminary cytotoxic assay was performed on the series of 3,5-diaryl N-acetyl-pyrazolines and only the potent 3,5-diaryl N-acetyl-pyrazolines were selected for their inclusion in the hybrid scaffold. Among the cell lines employed, HeLa cell line was the most sensitive towards the exposure of test compounds. Out of all the compounds evaluated, two right-handed conjugates MI-7b and MI-8b and two left-handed conjugates MI-4b, MI-6b displayed significant cytotoxic potential and exhibited an IC50 range from 1.3 to 3.5 mu M against HeLa Cell line..
• Sangwan, Naresh K.; Verma, Braham S.; Dhindsa, Kuldip Singh, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1993, vol. 32, # 4, p. 508 - 512
  作者：Sangwan, Naresh K.、Verma, Braham S.、Dhindsa, Kuldip Singh

  DOI：——

  日期：——
• Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin
  作者：Shenglin Luan、Hang Zhong、Xuan Zhao、Jinyu Yang、Yongkui Jing、Dan Liu、Linxiang Zhao

  DOI：10.1016/j.ejmech.2017.10.023

  日期：2017.12

  Twenty hybrid compounds, tethering dihydroartemisinin (DHA) with diaryl-pyrazoline/diaryl-pyrazole through ether linkage, were synthesized based on hybridization strategy and assessed for their anticancer activity. The representative compound 6f exhibited significantly elevated antiproliferative activity compared with DHA against a panel of cancer cell lines. Unexpected sensitivity of 6f in Adriamycinresistant MCF-7 cells (MCF-7/Adr) inspired subsequent research on anticancer activity of these DHA derivatives against breast cancer cell lines. All the novel compounds exhibited potent activity in three breast cancer cells including MDA-MB-231, MCF-7 and MCF-7/Adr. Most of them exerted almost 10-fold higher potency in MCF-7/Adr than in MCF-7 and MDA-MB-231 cells. Compound 5f, the most potent compound against MCF-7/Adr (GI(50) = 18 nM), was used for mechanism research which revealed that compound 5f arrested MCF-7 and MCF-7/Adr cells in G0/G1 phase with decreased levels of cyclin D1 and increased levels of p27. Preliminary pharmacokinetic properties of 5f and 6f were investigated in rats after a single intravenous administration. The high sensitivity of MCF-7/Adr indicates that these compounds have potential to be developed as therapeutic agents to treat drug-resistant cancer. (C) 2017 Published by Elsevier Masson SAS.